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Aims Co-primary objectives were to evaluate dalcetrapib (JTT-705/RO4607381), which targets cholesteryl ester transfer
protein (CETP), effects on high-density lipoprotein cholesterol (HDL-C) in participants with coronary heart disease
or risk equivalents and to evaluate potential changes in mesenteric lymph nodes.
Methods
and results
Double-blind trial with participants randomized (2:1) to dalcetrapib 900 mg/day (higher than 600 mg phase III dose)
or placebo, both with atorvastatin, for 24 weeks (n ¼ 135; one without post-baseline efﬁcacy data was excluded from
intent-to-treat population); a subset continued for 24-week extension (n ¼ 77). Lipid changes and safety parameters
were assessed. Mesenteric lymph nodes were evaluated by magnetic resonance imaging. Dalcetrapib increased
HDL-C (33.4%, Week 24; 33.8%, Week 48), decreased CETP activity (–53.5%, Week 24; –56.5%, Week 48), and
increased apolipoprotein A-I (11.4%, Week 24; 16.4%, Week 48). Dalcetrapib showed no clinically relevant
differences vs. placebo in adverse events, laboratory parameters including aldosterone, electrocardiograms, and vital
signs including blood pressure (BP). Dalcetrapib had no measurable, clinically relevant effect on lymph node size.
Conclusion Dalcetrapib 900 mg administered for up to 48 weeks showed no clinically relevant changes in lymph nodes, BP, or
other safety parameters. Dalcetrapib effectively increased HDL-C over 48 weeks of treatment.
-----------------------------------------------------------------------------------------------------------------------------------------------------------
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Introduction
Targeting high-density lipoprotein cholesterol (HDL-C) may
potentially reduce cardiovascular disease (CVD) events and risk
beyond the reduction already achieved with the standard of care,
which includes statins. This is based on the strong epidemiological
inverse relationship between HDL-C and CVD risk
1–3 together
with suggestive evidence from clinical trials with drugs that both
raise HDL-C and lower low-density lipoprotein cholesterol
(LDL-C).
4–6 However, current HDL-C-raising therapies have
either limited efﬁcacy or tolerability issues.
7
One potential strategy towards raising HDL-C is through inhi-
bition of cholesteryl ester transfer protein (CETP). Decreased
plasma levels of CETP are associated with increased levels of
HDL-C and, in turn, decreased risk of coronary artery disease
(CAD).
8–10 These effects have been correlated also with speciﬁc
mutations in the CETP gene.
8,11,12
Torcetrapib, the ﬁrstinhibitorofCETPactivity toenterextensive
evaluation in humans, was associated with increases in blood
pressure (BP) in several clinical trials, which appears to be a
compound-speciﬁc, off-target effect.
13–17 Notably, the phase III
Investigation of Lipid Level Management to Understand its Impact
inAtheroscleroticEvents(ILLUMINATE)trialoftorcetrapibincom-
bination with atorvastatin was halted very early due to increased
CVD events and all-cause mortality compared with atorvastatin
alone;
13 further development of torcetrapib was terminated.
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doi:10.1093/eurheartj/ehp601Clinical studies have shown that dalcetrapib either alone or with
pravastatin was associated with increased HDL-C but no effect on
BP.
18,19 A recent analysis of safety data at 4 and 12 weeks from ﬁve
phase II trials further reinforces the safety of dalcetrapib both alone
and in combination with statins
20 and supported further clinical
study of dalcetrapib. One potential safety concern from pre-clinical
studies surrounds dalcetrapib binding to lipoproteins, lipids, and
chylomicrons and ingestion by macrophages in mice and rats,
and to a lesser extent in monkeys and hamsters. Although depo-
sition of foamy macrophages in mesenteric lymph nodes is not
anticipated in humans, clinical studies are necessary to conﬁrm this.
Although dalcetrapib 600 mg/day is the dose selected for phase
III development, the 900 mg/day dose
18,20 was chosen for this
study in order to provide a robust assessment of safety and
tolerability.
Methods
Participants
Participants were aged 18–75 with coronary heart disease (CHD) or
CHD risk equivalents based on National Cholesterol Education
Program Adult Treatment Panel III guidelines (atherosclerosis, dia-
betes, or 10-year risk of CHD events .20%). For full inclusion/exclu-
sion criteria, see the Supplementary material online.
All participants provided written informed consent. Protocols (core
and extension periods) were approved by appropriate Institutional
Review Boards and Ethics Committees. The study was conducted in
10 centres in the USA and 5 in Germany in conformance with the prin-
ciples of the Declaration of Helsinki and International Conference of
Harmonization Good Clinical Practice guidelines.
Study design
This double-blind, randomized, placebo-controlled, parallel-group,
phase II trial included a 5–12-week pre-randomization phase, a
24-week core treatment phase (ClinicalTrial.gov identiﬁer:
NCT00353522), and an optional 24-week extension phase (Clinical-
Trial.gov identiﬁer: NCT00400439). Participants received atorvastatin
10–80 mg daily during the run-in period, those achieving LDL-C
,100 mg/dL were randomized to dalcetrapib 900 mg or placebo
(2:1) daily co-administered with atorvastatin 10–80 mg for 24 weeks.
Participants continuing in the extension phase received allocated treat-
ment for a further 24 weeks. The double-blind treatment period
included both core and extension phases.
Efﬁcacy
Primary efﬁcacy parameters were percent and absolute change from
baseline in HDL-C, measured at 24 weeks (core phase) and 48
weeks (extension phase) using standard methods.
21 Secondary efﬁcacy
parameters included changes in lipids, apolipoprotein A-I, CETP mass
and activity and high-sensitivity (hs) C-reactive protein (more details
are provided in the Supplementary material online).
Safety
Safety was assessed by monitoring of adverse events (AEs), vital signs,
physical examination, and laboratory safety measures (further details
are provided in the Supplementary material online). Patients who did
not return for a follow-up visit were contacted by the investigator
by telephone, personal visit, or via a responsible relative to determine
the reason for withdrawal.
Effect on mesenteric lymph nodes
One primary safety objective was to investigate the effect of longer-
term high-dose dalcetrapib on the size of mesenteric lymph nodes.
Unenhanced magnetic resonance imaging (MRI) (without oral or intra-
venous contrast administration) was performed using standardized
high resolution MRI scanners ( 1.5 T). MRI scans were performed
during pre-randomization and at 12, 24, 36, and 48 weeks. In addition
to assessment by a local radiologist, two independent blinded
reviewers assessed the MRI scans and determined the size of individual
lymph nodes based on the dimension of the shortest axis, with
,2 mm considered undetectable. Nodes were categorized according
to size change relative to previous visits.
Statistical analyses
Efﬁcacy
The primary efﬁcacy analysis was based on the intent-to-treat core and
extension populations. These included all randomized participants with
one or more post-baseline efﬁcacy measurements. For missing data at
Weeks 12 and 24, the last available post-randomization visit data were
carried forward for percentage change calculation (last observation
carried forward analysis). Treatment differences with respect to
mean values for the primary variable were estimated by standard
linear model methods (analysis of covariance), where dependent vari-
ables included treatment, centre, baseline value of the primary variable,
and their interaction terms as appropriate. Ninety-ﬁve per cent
two-sided conﬁdence interval estimates and associated P-values for
treatment differences were calculated for model-based exploratory
parameters. The non-parametric Wilcoxon two-sample test was
used to test for differences in hs-C-reactive protein between treat-
ment groups. No adjustments were made for multiple comparisons.
Safety
The safety population included all randomized participants who
received one or more doses of study medication and had a safety
follow-up visit. Descriptive statistics are presented. No inferential stat-
istical analyses were performed.
Sample size
Since the primary purpose of the study was exploratory to examine
potential effects on mesenteric lymph nodes, it was not possible to cal-
culate sample size based upon formal power calculations relative to the
expected effects on this end point. Accordingly, the study sample size
was based upon being able to evaluate changes in HDL-C over a
24-week period (due to its importance as an efﬁcacy end point in
establishing beneﬁt to patients); thus, the sample size was planned
on the basis of studies conducted to date. An initial sample of 105
patients (70 on active treatment, 35 receiving placebo) was anticipated
to ensure adequate precision for estimating differences with regard to
efﬁcacy between treatment groups.
Statistical analyses were performed with SAS software (SAS
Institute Inc.).
Results
Analysis populations
Overall, 135 participants (89 dalcetrapib and 46 placebo) were
enrolled. All 135 patients were included in the 24-week core
safety population, with 134 in the intent-to-treat population
(placebo, n ¼ 1 excluded as no post-baseline efﬁcacy data)
(Figure 1). Patients deﬁned as withdrawn from the study
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vation carried forward. During the ﬁrst month of treatment, two
patients in each group withdrew from the study (one due to AE/
intercurrent illness, one withdrew consent). There were no appar-
ent differences between the two groups in terms of when patients
were withdrawn. The 24-week extension phase included 77 par-
ticipants in both the intent-to-treat and safety extension popu-
lations (52 dalcetrapib and 25 placebo) and was limited to US
sites as the extension protocol lacked approval from the
German Federal Institute for Drugs and Medical Devices
(Bundesinstitut fu ¨r Arzneimittel und Medizinprodukte) based on
available data. Treatment groups were generally comparable with
regard to baseline characteristics (Table 1). Slightly more dalcetra-
pib participants in both phases had previous coronary disease or
atherosclerosis vs. placebo; a similar trend was seen in this group
in the core period regarding previous hypertension.
Efﬁcacy
There was a signiﬁcantly greater increase in HDL-C from baseline
with dalcetrapib at Weeks 24 and 48 (each P , 0.0001 vs. placebo;
Table 2). The absolute change in HDL-C (least squares mean) with
dalcetrapib was 12.8 mg/dL at Week 24 and 13.8 mg/dL at Week
48 from baseline levels of 41.4 and 42.4 mg/dL, respectively. The
absolute change for placebo was 0.5 mg/dL at Week 24 and
1.4 mg/dL at Week 48 from baseline 41.0 and 41.8 mg/dL, respect-
ively. Percent change in HDL-C was 33.4% for dalcetrapib vs. 3.5%
for placebo at Week 24, and 33.8 vs. 3.7% at Week 48 (each P ,
0.0001 vs. placebo; Table 2). High-density lipoprotein cholesterol
levels reached a plateau at Week 2 with dalcetrapib and were sus-
tained throughout both treatment phases (Figure 2). In the dalce-
trapib group, CETP activity decreased (253.5% at Week 24;
256.5% at Week 48) and CETP mass increased (80.8% at Week
24; 86.5% at Week 48) from baseline (each P , 0.0001 vs.
placebo; Table 2).
At Weeks 24 and 48 with dalcetrapib, there were no clinically
relevant changes from the already low baseline LDL-C levels on
atorvastatin of 76.9 and 74.2 mg/dL, respectively (Table 2). At
Week 24, triglyceride levels were elevated with placebo but not
dalcetrapib (19 vs. 21.5%; P ¼ 0.006; Table 2) from baseline
131.7 and 150.2 mg/dL, respectively; this difference between
groups was not consistently observed (data not shown). Apolipo-
protein A-I increased from baseline in both groups; this was signiﬁ-
cantly greater for dalcetrapib vs. placebo at both Week 24 (11.4 vs.
4.4%; P ¼ 0.006) and Week 48 (16.4 vs. 8.2%; P ¼ 0.025; Table 2).
Figure 1 Participant disposition. Asterisk indicates the most common reason for exclusion (51%) pre-randomization was disqualiﬁcation on
the basis of non-detection of lymph nodes;
†n ¼ 45 for intent-to-treat; one participant in the placebo group was excluded from the
intent-to-treat population due to lack of post-baseline efﬁcacy data.
E.A. Stein et al. 482There was a small but statistically signiﬁcant difference between
treatment groups in median percent change in hs-C-reactive
protein from baseline at Week 24 (P ¼ 0.010 absolute change;
P ¼ 0.008 percent change) but not at Week 48 (Table 2). These
data proved difﬁcult to interpret due to differences in the
median hs-C-reactive protein values at baseline between dalcetra-
pib (1.44 mg/L) and placebo (1.57 mg/L) groups in the 48-week
study, with hs-C-reactive protein levels possibly attenuated by
atorvastatin treatment (Table 1).
Safety
Adverse events
During the double-blind treatment period, which included both
the core and extension periods, the percentage of participants
........................................................ ........................................................
...............................................................................................................................................................................
Table 1 Demographics and baseline characteristics following pre-randomization phase
Parameter
a 24-week core phase 24-week extension phase
Placebo Dalcetrapib 900 mg Placebo Dalcetrapib 900 mg
n 46 89 25 52
Age (years) 60.2+7.50 61.2+7.76 60.8+7.83 60.6+7.03
Gender, male (%) 38 (83) 68 (76) 22 (88) 40 (77)
Body mass index (kg/m
2) 30.1+5.59 30.5+4.73 29.7+6.04 30.1+4.64
Systolic BP (mmHg) 125.2+14.31 128.1+13.57 125.2+13.57 126.7+14.11
Diastolic BP (mmHg) 75.8+7.25 75.6+8.19 76.2+7.68 76.0+8.92
HDL-C (mg/dL) 41.0+11.4 41.4+9.31 41.8+12.5 42.4+9.42
LDL-C (mg/dL) 76.9+20.7 76.9+16.4 78.9+23.7 74.2+17.1
Total cholesterol (mg/dL) 144.2+26.03 147.3+22.26 150.6+29.25 143.8+19.86
Triglyceride (mg/dL) 131.7+69.72 150.2+92.57 149.9+80.46 136.0+56.48
Apolipoprotein A-I (mg/dL) 131.9+23.41 137.1+17.07 133.8+23.75 138.4+16.59
hs-C-reactive protein (mg/L)
b 1.30 (2.45) 1.27 (2.86) 1.57 (4.49) 1.44 (3.04)
CETP activity (pmol/mL/h) 26.1+8.30 26.3+7.87 27.0+7.95 27.1+8.79
CETP mass (mg/mL) 1.7+0.4 1.7+0.4 1.7+0.4 1.6+0.4
Cigarette smoker (%) 4 (9) 14 (16) 3 (12) 6 (12)
Hypertension (%) 30 (65) 65 (73) 18 (72) 36 (69)
Diabetes (%) 25 (54) 48 (54) 13 (52) 28 (54)
Coronary disease (%) 19 (41) 49 (55) 11 (44) 28 (54)
Atherosclerosis (%) 15 (33) 35 (39) 7 (28) 23 (44)
BP, blood pressure; CETP, cholesteryl ester transfer protein; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol.
aMean+SD values unless otherwise stated.
bMedian values (inter-quartile range).
.........................................................................................................................................
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Table 2 Change from baseline for efﬁcacy parameters
Parameter
a Change (% change) from baseline
24-week core phase 24-week extension phase
Placebo Dalcetrapib
900 mg
P-value Placebo Dalcetrapib
900 mg
P-value
HDL-C (mg/dL) 0.5 (3.5) 12.8 (33.4) ,0.0001 (,0.0001) 1.4 (3.7) 13.8 (33.8) ,0.0001 (,0.0001)
LDL-C (mg/dL) 1.5 (5.6) 21.1 (0.5) 0.466 (0.270) 20.9 (3.0) 1.6 (4.8) 0.585 (0.781)
Triglyceride (mg/dL) 3.9 (19.0) 212.5 (21.5) 0.116 (0.006) 29.0 (4.1) 22.5 (0.9) 0.807 (0.801)
Apolipoprotein A-I (mg/dL) 4.2 (4.4) 14.8 (11.4) 0.002 (0.006) 9.8 (8.2) 22.0 (16.4) 0.010 (0.025)
hs-C-reactive protein (mg/L)
b 20.24 (224.2) 0.05 (5.7) 0.010 (0.008) 20.24 (226.1) 0.01 (3.2) 0.114 (0.146)
CETP activity (pmol/mL/h) 20.1 (2.0) 214.4 (253.5) ,0.0001 (,0.0001) 22.2 (25.7) 215.3 (256.5) ,0.0001 (,0.0001)
CETP mass (mg/mL) 20.02 (20.8) 1.4 (80.8) ,0.0001 (,0.0001) 20.1 (24.9) 1.4 (86.5) ,0.0001 (,0.0001)
CETP, cholesteryl ester transfer protein; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol.
aLeast squares mean change (% change) from baseline, unless otherwise stated.
bMedian (per cent change) from baseline.
48-Week safety and tolerability of dalcetrapib 483experiencing at least one AE was comparable between dalcetrapib
900 mg (85%) and placebo (83%), and most AEs were mild or
moderate in intensity, with no deaths (Table 3). This trend was
apparent also between treatment groups for the incidence of com-
monly occurring AEs (Table 4). Diarrhoea was the most common
AE with dalcetrapib, occurring more frequently than for placebo
(17 vs. 11%; Table 4). Although extremity pain was slightly more
common with dalcetrapib vs. placebo (10 vs. 4%; ns), the incidence
of myalgia was low in each group (4%). The percentage of AEs con-
sidered related to treatment was comparable between dalcetrapib
(39%) and placebo (33%) (Table 3). Diarrhoea and headache were
the most common treatment-related AEs reported with dalcetra-
pib (13 and 6%, respectively).
The percentage of participants experiencing serious AEs (SAEs)
was comparable between treatment groups (11% dalcetrapib vs.
9% placebo) (Table 3). One case of CAD with dalcetrapib was con-
sidered possibly related to treatment by the investigator. All other
Figure 2 High-density lipoprotein cholesterol per cent change (+95% conﬁdence interval) from baseline (BL) by time over 48 weeks.
....................................
................................................................................
Table 3 Overview of adverse events in the
double-blind treatment period (core and extension
periods)
Number (%) of participants
with  1A E
Placebo Dalcetrapib
900 mg
n 46 89
Any AE 38 (83) 76 (85)
Mild 26 (57) 63 (71)
Moderate 24 (52) 52 (58)
Severe 3 (7) 15 (17)
Treatment-related AEs 15 (33) 35 (39)
Serious AE 4 (9) 10 (11)
Deaths 0 0
Withdrawals due to AEs 3 (7) 11 (12)
Withdrawals due to
treatment-related AEs
2 (4) 8 (9)
.......................................
................................................................................
Table 4 Most frequently reported adverse events (ﬁve
or more cases in any treatment group)
Number (%) of participants
with  1A E
Placebo Dalcetrapib
900 mg
n 46 89
Diarrhoea 5 (11) 15 (17)
Upper respiratory tract infection 6 (13) 13 (15)
Nasopharyngitis 4 (9) 9 (10)
Pain in extremity 2 (4) 9 (10)
Back pain 4 (9) 7 (8)
Headache 3 (7) 7 (8)
Arthralgia 2 (4) 6 (7)
Abdominal pain 3 (7) 5 (6)
Sinusitis 3 (7) 5 (6)
Hypertension 1 (2) 5 (6)
E.A. Stein et al. 484SAEs were considered not related to treatment [dalcetrapib: atrial
ﬁbrillation (two participants), non-cardiac chest pain (two partici-
pants), angina pectoris, glioma, metastatic squamous cell carci-
noma, rectal cancer, neurocysticercosis; placebo: CAD, arthritis,
osteoarthritis, acute cholecystitis]. The participant with metastatic
squamous cell carcinoma had a history of the disease. Adverse
events led to the withdrawal of 12% of participants administered
dalcetrapib and 7% of participants given placebo (ns; Table 3).
This included one participant who permanently discontinued dal-
cetrapib due to an AE (myalgia) which started before the double-
blind study. The percentage of participants who withdrew due to
treatment-related AEs was 9% for dalcetrapib and 4% for
placebo (Table 3). Regarding cardiac and vascular AEs, CAD, and
two cases of hypertension in the dalcetrapib group were con-
sidered possibly treatment-related.
Blood pressure, heart rate, and electrocardiograms
Blood pressure remained stable throughout the 48-week study
(Figure 3). Mean (SD) BP values for dalcetrapib were (systolic BP/
diastolic BP) 127 (14.1)/76 (8.9) mmHg at baseline and 127 (12.6)/
77 (11.1) mmHg at study end. Shifts in systolic BP and diastolic BP
were of a similar magnitude and direction in both treatment
groups. Pulse rates generally remained stable (data not shown).
In the dalcetrapib group, increased heart rate and irregular heart
rate were each experienced by one participant. Two participants
administered dalcetrapib had abnormal electrocardiograms, one
of which was considered remotely related to treatment.
Laboratory tests
Four percent of participants in each treatment group experienced
elevations in creatine phosphokinase (CPK), alanine aminotransfer-
ase (ALT), or aspartate aminotransferase (AST). In the dalcetrapib
group, CPK elevations .3   upper limit of normal (ULN) were
observed in 2% (2/89) of participants and CPK elevations .5  
ULN in 1% (1/89) of participants; also with elevated levels at base-
line (.1 but ,3   ULN). In the placebo group, 2% (1/45) of par-
ticipants experienced CPK elevations .3   ULN. Additionally, 1%
(1/89) of participants administered dalcetrapib experienced ALT
elevations .3   ULN, and 2% (1/45) of participants administered
placebo experienced elevations in both ALT (.5   ULN) and
AST (.5   ULN). Aspartate aminotransferase elevations .3  
ULN were not observed with dalcetrapib. No participants with
CPK elevations experienced myalgia, and no participant perma-
nently discontinued treatment due to liver enzyme elevations.
Treatment was interrupted for one dalcetrapib participant due
to increased (.3   ULN) levels of alkaline phosphatase (ALP),
Figure 3 Blood pressure over time in the 24-week core and 24-week extension study.
48-Week safety and tolerability of dalcetrapib 485ALT, and gamma-glutamyl transferase (GGT) on Day 19. This par-
ticipant also had elevated ALP and GGT levels on Days 22, 28, 37,
55, 70, and 118, which progressively returned to normal. Elevation
in ALP . 3   ULN on Days 19 and 22 was not considered clini-
cally signiﬁcant (the deﬁnition being ALP and AST .3   ULN
on two occasions  4 days apart). The AE was considered mild
and possibly related to treatment by the investigator and resolved
without sequelae.
There were no clinically signiﬁcant changes in electrolytes with
dalcetrapib; mean (SD) potassium and sodium levels were 4.3
(0.35) and 141 (2.1) mmol/L, respectively, at baseline and 4.3
(0.42) and 141 (2.3) mmol/L, respectively, at study end. In the
placebo group, mean (SD) potassium and sodium levels were 4.3
(0.46) and 141 (2.0) mmol/L, respectively, at baseline and 4.4
(0.45) and 141 (2.8) mmol/L, respectively, at study end.
Aldosterone levels showed no change; median levels at baseline
and study end were 76 and 82 pg/mL, respectively, with dalcetrapib,
and 100 and 96 pg/mL, respectively, with placebo.
Effects on mesenteric lymph nodes
At randomization, 70 participants in the dalcetrapib group and 33
participants in the placebo group had a detectable mesenteric
lymph node, as anticipated given this was an entry requirement
for the trial. When the sizes of mesenteric lymph nodes were com-
pared at various times during the study, similar results were
obtained in the placebo and dalcetrapib groups. A comparison of
changes in lymph node volume from baseline to Week 48 reported
that in the placebo group, of 32 nodes assessed, 56% decreased in
size, 3% stayed the same and 41% increased. In the dalcetrapib
group where 45 nodes were assessed, similar percentages of
lymph nodes increased (42%) and decreased (56%) in size and
there was no clinically relevant difference in the proportion of
enlarged lymph nodes. The Data Safety Monitoring Board con-
cluded that there were no systematic or signiﬁcant safety concerns
in the MRI data at Week 24. Similarly, data from review of the MRI
scans at Week 48 were consistent with the Week 24 data and did
not show any trend towards an increase or decrease in lymph
node size in either treatment group.
Discussion
Cholesteryl ester transfer protein has been identiﬁed as a potential
therapeutic target to improve CVD outcomes. However, recent
clinical studies with torcetrapib have raised questions regarding
the safety of this approach, as torcetrapib has been associated
with increases in BP, CVD events, and mortality,
13–16 although
studies with other CETP inhibitors have indicated that these are
not class effects.
17 Indeed, previous pre-clinical and clinical work
with dalcetrapib has shown no effect on mean BP over 12
weeks.
20,22 These ﬁndings, with a dose 50% higher than that
used in ongoing development, have been extended out to 48
weeks in this study, which is the longest study to date of a CETP-
targeting agent with no detected changes in BP. Additionally, in
contrast with torcetrapib, the observed increase in HDL-C with
dalcetrapib reached a maximum at approximately 2 weeks; torce-
trapib showed a continuing increase in HDL-C after 3 months of
treatment in the ILLUMINATE trial.
13
The current study presents additional safety data for an agent
that targets CETP ahead of the ongoing large phase III
dal-OUTCOMES trial.
23 In this analysis, dalcetrapib was found
not to be associated with any clinically relevant safety concerns
with regard to overall or cardiovascular AEs. The incidence of
SAEs in the two treatment groups was comparable between the
groups (11% dalcetrapib; 9% placebo); absolute numbers (n ¼ 10
dalcetrapib; n ¼ 4 placebo) and numbers of participants (n ¼ 89
dalcetrapib; n ¼ 45 placebo) were greater in the dalcetrapib
group mainly due to a 2:1 randomization. The inclusion of only par-
ticipants with CHD or risk equivalents would also be expected to
result in some cardiovascular SAEs. Although cardiovascular SAEs
were slightly more common in the dalcetrapib group, this may
reﬂect the greater pre-ponderance of CHD risk factors in the dal-
cetrapib group at baseline. The slightly higher incidence of
reported hypertension in the dalcetrapib group compared with
the placebo group may indeed have been due to baseline differ-
ences. None of the three carcinoma-associated events in the
dalcetrapib group were treatment-related—in two cases these
were thought likely to be pre-existing disease (the presence of
skin lesions was not an exclusion criteria in the case of the meta-
static squamous cell carcinoma, and diagnosis of a case of rectal
cancer early in the trial suggested it was present at baseline);
glioma was diagnosed in another patient (Day 334) following an
episode of dementia. Data from a previous 12-week study
showed no cases of cancer with dalcetrapib in combination with
pravastatin.
20 Although there were differences in the type of
SAEs between the treatment groups, it is difﬁcult to draw any con-
clusions from these differences due to the relatively small number
of participants and the 2:1 randomization.
In this study, the use of dalcetrapib to inhibit CETP activity did
not appear to be associated with any off-target, compound-
speciﬁc, cardiovascular or non-cardiovascular safety concerns,
except for an increased incidence of gastrointestinal events and
headache. While a pre-clinical lymph node signal observed in
some but not all species was considered unlikely to be clinically sig-
niﬁcant, this study conﬁrmed that dalcetrapib has no effect on
lymph nodes in humans. In addition, the dose of dalcetrapib
studied (900 mg) was higher than the 600 mg dose chosen for
further development and the placebo-controlled phase III
dal-OUTCOMES trial, in which dalcetrapib is being evaluated in
clinically stable patients with recent acute coronary syndrome
(ACS) (n ¼ 15 600) in combination with a background of standard
ACS medication.
23 The lack of substantial AEs at a 900 mg dose
provides support for the safety of dalcetrapib in phase III trials.
The safety data reported here corroborate the results of a safety
analysis of ﬁve shorter phase II trials examining dalcetrapib at doses
of 300, 600, and 900 mg compared with placebo: a 4-week trial of
dalcetrapib alone (n ¼ 193), three 4-week studies of dalcetrapib in
combination with statins (n ¼ 353), and a 12-week trial of dalcetra-
pibincombinationwithpravastatin(n ¼ 292).
20Theanalysisshowed
a similar low incidence of cardiovascular AEs ( 5%) in the different
treatment groups.
20 In the pooled 4-week trials, the incidence of
patients with AEs with the 600 mg dose of dalcetrapib was the
same as with placebo, but it was higher with dalcetrapib 900 mg
(P , 0.05 vs. placebo and vs. dalcetrapib 600 mg).
20 The incidence
of SAEs was low (1% in each treatment group including placebo).
20
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be substantially reduced with the phase III 600 mg dose compared
with the 900 mg dose investigated here. Although there was some
degree of dose dependence in the effect of dalcetrapib on HDL-C
in other phase II trials,
18–20 the increase in HDL-C observed with
dalcetrapib 600 mg in combination with a statin (pravastatin) was
as high as 31.4% at 12 weeks of treatment.
20 This is only slightly
below the increases observed in the current study with dalcetrapib
900 mg (33.4% at Week 24; 33.8% at Week 48). Signiﬁcant
increases in apolipoprotein A-I for dalcetrapib vs. placebo were
also observed in this study. Although hs-C-reactive protein was
not signiﬁcantly increased from baseline after 24 or 48 weeks of
dalcetrapib therapy, the placebo group experienced a slight
decrease, which at 24 weeks resulted in a statistical difference
between the groups which was not present at 48 weeks. The clini-
cal signiﬁcance of these ﬁndings is uncertain.
Notably, the number of participants studied to date having taken
dalcetrapib is limited and follow-up is relatively short. Accordingly,
thepossibilityofTypeIIerrorcannotberuledout.Additional,larger
studies are needed to deﬁnitively determine whether there may be
important adverse effects associated with the use of dalcetrapib.
In conclusion, this 48-week safety trial, the longest to date, pro-
vides additional support that dalcetrapib appears to be a safe and
effective HDL-C-raising treatment. An exploratory analysis is
planned to analyse a surrogate CHD endpoint, changes in aortic
plaque morphology, from the MRI scans obtained in this study.
Further study is also underway to determine whether the
increases observed in HDL-C with dalcetrapib will lead to
improved morbidity and mortality outcomes
23 (ClinicalTrial.gov
identiﬁer: NCT00658515).
Supplementary material
Supplementary material is available at European Heart Journal
online.
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Simultaneous quadruple kissing stenting of an unprotected left main
coronary artery
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Coronary angiography for non-ST-elevation
myocardial infarction in a 83-year-old,
obese, hypertensive woman with diabetic
nephropathy and hyperlipidaemia revealed
a severe stenosis in a very large calibre
unprotected distal left main coronary
artery (LMCA) (arrows in Panels A–C) invol-
ving an uncommon quadrifurcation with the
left anterior descending (LAD), two inter-
mediate branches, and the Circumﬂex (Cx)
artery. A long segment of the proximal
LAD (asterisk) and the ostium of the most
medial intermediate branch were also criti-
cally diseased. Although diabetic state and
anatomic considerations would highly
suggest coronary artery bypass graft
surgery as the preferred treatment strategy,
the patient was rejected for surgery due to
morbid obesity, age, and renal failure.
Hence, we planned a percutaneous
coronary intervention after obtaining
informed consent and after checking efﬁcacy
of dual antiplatelet treatment by platelet
aggregometry and willingness of treatment compliance.
We opted for a simultaneous kissing stenting technique due to the important size mismatch between LMCA and distal branches. To
allow simultaneous introduction of four stents in the LMCA, we used a bilateral 8 French arterial access (arrowheads in Panels D–F)
and wired all branches 2 by 2. First, the LAD was separately treated with a TAXUS Liberte ´ 3.0/38 mm paclitaxel-eluting stent (Boston
Scientiﬁc), leaving the ostial segment unstented. Consequently, four TAXUS Liberte ´ stents were introduced in the LMCA quadrifurca-
tion (3.0/12, 2.75/16, 2.5/12, and 2.75/12 in LAD, medial and lateral intermediate branch and the Cx, respectively; Panel D), followed by
simultaneous quadruple kissing stent expansion at 12 atm each (Panels E and F). Final angiography conﬁrmed wide patency of LMCA
and all four branches (Panels G–I).
Published on behalf of the European Society of Cardiology. All rights reserved. & The Author 2009. For permissions please email: journals.permissions@oxfordjournals.org.
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